CX-801
Oncology
Phase 1Active
Key Facts
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology company leveraging its proprietary Probody® platform to develop conditionally activated therapeutics designed to minimize off-tumor toxicity. The company has built a diversified pipeline of eight candidates, including key clinical-stage assets like CX-904 (EGFRxCD3 T-cell engager) and CX-2051 (EpCAM ADC), supported by strategic partnerships with major pharmaceutical firms such as Amgen, AbbVie, and Bristol Myers Squibb. CytomX's strategy combines internal development of wholly-owned assets with a capital-efficient partnership model to validate and expand the application of its platform technology across multiple therapeutic modalities.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |